
### [NCIT:C8853](http://purl.obolibrary.org/obo/NCIT_C8853)
**Label:** Refractory Diffuse Large B-Cell Lymphoma

**Subclasses:** [NCIT:C8927](http://purl.obolibrary.org/obo/NCIT_C8927) (Refractory Centroblastic Lymphoma), [NCIT:C138028](http://purl.obolibrary.org/obo/NCIT_C138028) (Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type), [NCIT:C138026](http://purl.obolibrary.org/obo/NCIT_C138026) (Refractory Intravascular Large B-Cell Lymphoma), 

**Class expressions from DL-Learner:**

- Thing 53.75%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38171](http://purl.obolibrary.org/obo/NCIT_C38171) (PKCbeta1 Messenger RNA Overexpression))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38170](http://purl.obolibrary.org/obo/NCIT_C38170) (LMO2 Messenger RNA Overexpression))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38169](http://purl.obolibrary.org/obo/NCIT_C38169) (A-myb Messenger RNA Overexpression))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38168](http://purl.obolibrary.org/obo/NCIT_C38168) (BCL-6 Messenger RNA Overexpression))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38167](http://purl.obolibrary.org/obo/NCIT_C38167) (CD10 Messenger RNA Overexpression))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38158](http://purl.obolibrary.org/obo/NCIT_C38158) (Metachronous Wilms Tumor))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38157](http://purl.obolibrary.org/obo/NCIT_C38157) (Metachronous Osteosarcoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38155](http://purl.obolibrary.org/obo/NCIT_C38155) (Recurrent Disease))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38111](http://purl.obolibrary.org/obo/NCIT_C38111) (Skin Sarcomatoid Basal Cell Carcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38110](http://purl.obolibrary.org/obo/NCIT_C38110) (Skin Signet Ring Cell Basal Cell Carcinoma))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38107](http://purl.obolibrary.org/obo/NCIT_C38107) (Dedifferentiated Dermatofibrosarcoma Protuberans))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38106](http://purl.obolibrary.org/obo/NCIT_C38106) (Myxoid Dermatofibrosarcoma Protuberans))) 37.63%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C38043](http://purl.obolibrary.org/obo/NCIT_C38043) (Typhlitis))) 37.63%


